Independent prognostic role of p16 expression in lung cancer

被引:28
作者
Groeger, AM
Caputi, M
Esposito, V
De Luca, A
Bagella, L
Pacilio, C
Klepetko, W
Giordano, GG
Baldi, F
Kaiser, HE
Wolner, E
Giordano, A
机构
[1] Thomas Jefferson Univ, Jefferson Med Coll, Sbarro Inst Canc Res & Mol Med, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA
[2] Univ Vienna, Dept Cardiothorac Surg, Vienna, Austria
[3] Univ Naples 2, Dept Resp Dis, Naples, Italy
[4] Ist Regina Elena, Ctr Expt Res, Lab Cell Metab & Pharmacokinet, I-00161 Rome, Italy
[5] Univ Naples Federico II, Dept Anat Pathol, Naples, Italy
[6] Univ Maryland, Dept Pathol, Baltimore, MD 21201 USA
[7] Univ Vienna, Dept Expt Pathol, Vienna, Austria
基金
美国国家卫生研究院;
关键词
D O I
10.1016/S0022-5223(99)70192-3
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: The cyclin-dependent kinase p16 (also known as Ink4A, Mts1, Cdkn2, and Cdkn4i) has been proposed as a tumor suppressor gene mapped on chromosome segment 9p21, This study evaluated p16 protein expression in 135 lung cancer specimens and investigated potential genetic alterations occurring in this gene. Results: We found altered p16 immunohistochemical expression to be a frequent event in lung cancer and to be independent of either the histologic type or any other clinical-pathologic feature, Western blot analyses performed on about one third of the specimens correlated highly with these results, In addition, we found p16 immunohistochemical expression to be a favorable prognostic factor in lung cancer in that its reduction or loss correlated with a worse outcome for the patients. Polymerase chain reaction amplification and direct sequencing of p16 exons 1 and 2 revealed no mutations, indicating that p16-altered expression in lung cancer is not necessarily linked to mutational events of these genes. Conclusions: We conclude that p16-altered expression is both an independent and frequent event in lung cancer and may have an important role in tumorigenesis and in malignant progression of a significant proportion of these cancers. However, the actual incidence and relevance of p16 mutations in this neoplasm continues to be debated, and its analysis seems inconclusive, Our results suggest a prognostic role for the immunodetection of this protein on formalin-fixed and paraffin-embedded specimens. They further suggest its routine use in the evaluation of the frequently unpredictable behavior of lung cancer.
引用
收藏
页码:529 / 535
页数:7
相关论文
共 26 条
[1]   FREQUENT MUTATIONS OF CDKN2 IN PRIMARY PANCREATIC ADENOCARCINOMAS [J].
BARTSCH, D ;
SHEVLIN, DW ;
TUNG, WS ;
KISKER, O ;
WELLS, SA ;
GOODFELLOW, PJ .
GENES CHROMOSOMES & CANCER, 1995, 14 (03) :189-195
[2]  
BEAHRS OH, 1992, LUNG MANUAL STAGING, P115
[3]   INFREQUENT CDKN2 (MTS1/P16) GENE ALTERATIONS IN HUMAN PRIMARY BREAST-CANCER [J].
BERNS, EMJJ ;
KLIJN, JGM ;
SMID, M ;
VANSTAVEREN, IL ;
GRUIS, NA ;
FOEKENS, JA .
BRITISH JOURNAL OF CANCER, 1995, 72 (04) :964-967
[4]   p21waf1/cip1mda-6 expression in non-small-cell lung cancer:: Relationship to survival [J].
Caputi, M ;
Esposito, V ;
Baldi, A ;
De Luca, A ;
Dean, C ;
Signoriello, G ;
Baldi, F ;
Giordano, A .
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 1998, 18 (02) :213-217
[5]  
DEVOS S, 1995, GENE CHROMOSOME CANC, V14, P164
[6]  
Esposito V, 1997, CANCER RES, V57, P3381
[7]  
Geradts J, 1996, AM J PATHOL, V149, P15
[8]  
GERADTS J, 1995, CANCER RES, V55, P6006
[9]  
IGAKI H, 1995, CANCER RES, V55, P4321
[10]  
Jarrard DF, 1997, GENE CHROMOSOME CANC, V19, P90, DOI 10.1002/(SICI)1098-2264(199706)19:2<90::AID-GCC4>3.3.CO